AMBER STUTZMAN: Open Payments
NPI 1811566169 · ALBION, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$228 in 13 payments from 9 companies in 2025. Trend: 2023 $190 · 2024 $95 · 2025 $228
Food & beverage: $228
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 3 | $55 |
| Supernus Pharmaceuticals, Inc. | 3 | $51 |
| Corcept Therapeutics | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| ABBVIE INC. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Corium, LLC | 1 | $10 |
Products named: Qelbree, Korlym, CAPLYTA, INGREZZA, Auvelity, VRAYLAR, TRINTELLIX, Azstarys.
Industry payments across IN — which companies pay providers there.
